Advanced Solid Tumors Clinical Trials in Fairfax, Virginia

25 studies are recruiting for advanced solid tumors in Fairfax, Virginia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT - Virginia, Fairfax, Virginia

   Locations

   9 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07349537 on ClinicalTrials.gov

2. First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

   The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Virginia, Fairfax, Virginia

   Locations

   9 in total

   Run by

   Accent Therapeutics

   See if you can join NCT06799065 on ClinicalTrials.gov

3. A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

   This is a study evaluating the safety, pharmacokinetics, and efficacy of calderasib alone, and calderasib plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Virginia ( Site 0271), Fairfax, Virginia

   Locations

   75 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT05067283 on ClinicalTrials.gov

4. A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

   The goal of this interventional study is to evaluate the safety and tolerability of escalating doses of FORX-428 as monotherapy in patients with select advanced solid tumors with BRCA1/2 mutations or other DDR deficiencies or high replication stress, and to determine the maximum tolerated dose (MTD…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT - Virginia Cancer Specialists, Fairfax, Virginia

   Locations

   8 in total

   Run by

   FoRx Therapeutics AG

   See if you can join NCT07356453 on ClinicalTrials.gov

5. Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

   The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Virginia, Fairfax, Virginia

   Locations

   22 in total

   Run by

   Pyxis Oncology, Inc

   See if you can join NCT06795412 on ClinicalTrials.gov

6. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

   The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Inova Schar Cancer Institute, Fairfax, Virginia

   Locations

   181 in total

   Run by

   American Society of Clinical Oncology

   See if you can join NCT02693535 on ClinicalTrials.gov

7. A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

   The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety of SC rilvegostomig in adult participants with advanced solid tumors previously treated with stand…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Fairfax, Virginia

   Locations

   11 in total

   Run by

   AstraZeneca

   See if you can join NCT07161414 on ClinicalTrials.gov

8. First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors

   This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determine the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology Virginia, Fairfax, Virginia

   Locations

   12 in total

   Run by

   VelaVigo Bio Inc

   See if you can join NCT07700160 on ClinicalTrials.gov

9. A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

   This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Fairfax, Virginia

   Locations

   7 in total

   Run by

   Samsung Bioepis Co., Ltd.

   See if you can join NCT07524348 on ClinicalTrials.gov

10. A Study of PHST001 in Advanced Solid Tumors

    This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced rela…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology - Virginia, Fairfax, Virginia

    Locations

    20 in total

    Run by

    Pheast Therapeutics

    See if you can join NCT06840886 on ClinicalTrials.gov

11. A Study of PHN-012 in Patients With Advanced Solid Tumors

    This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    PHN-012-001 Site, Fairfax, Virginia

    Locations

    26 in total

    Run by

    Pheon Therapeutics

    See if you can join NCT07127874 on ClinicalTrials.gov

12. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Virginia, Fairfax, Virginia

    Locations

    9 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT07397338 on ClinicalTrials.gov

13. A Study of ASP1002 in Adults for Treatment of Solid Tumors

    ASP1002 is being studied in people with tumors that have spread to nearby tissue (locally advanced) that cannot be removed by surgery (unresectable) or tumors that have spread to other parts of the body (metastatic). Claudin 4 protein, or CLDN4, is a protein found on tumors in different parts of th…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology Virginia, Fairfax, Virginia

    Locations

    15 in total

    Run by

    Astellas Pharma Global Development, Inc.

    See if you can join NCT05719558 on ClinicalTrials.gov

14. Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

    Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT, Fairfax, Virginia

    Locations

    15 in total

    Run by

    Ensem Therapeutics

    See if you can join NCT06993844 on ClinicalTrials.gov

15. A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

    The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Fairfax, Virginia

    Locations

    12 in total

    Run by

    Alterome Therapeutics, Inc.

    See if you can join NCT06835569 on ClinicalTrials.gov

16. An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

    The primary objectives of this trial are to: * Characterize the safety and tolerability of TEV-56278 * Determine the Recommended Phase 2 Dose (RP2D) * Evaluate antitumor activity of TEV-56278 (Part 2 only) * Determine the safety and tolerability of TEV-56278 in combination with pembrolizumab * Dete…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Teva Investigational Site 12018, Fairfax, Virginia

    Locations

    12 in total

    Run by

    Teva Branded Pharmaceutical Products R&D LLC

    See if you can join NCT06480552 on ClinicalTrials.gov

17. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology Virginia, Fairfax, Virginia

    Locations

    17 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT06040541 on ClinicalTrials.gov

18. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Next Oncology Virginia, Fairfax, Virginia

    Locations

    21 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT05379985 on ClinicalTrials.gov

19. A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

    A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Virginia, Fairfax, Virginia

    Locations

    26 in total

    Run by

    Vividion Therapeutics, Inc.

    See if you can join NCT05954312 on ClinicalTrials.gov

20. Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

    The main goal of this first-in-human (FIH) study is to learn about the safety and dosing of GS-2121 when given alone or in combination with zimberelimab (ZIM) in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of GS-2121 as …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Virginia, Fairfax, Virginia

    Locations

    6 in total

    Run by

    Gilead Sciences

    See if you can join NCT06532565 on ClinicalTrials.gov

21. Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

    The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary antitumor activity.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Virginia, Fairfax, Virginia

    Locations

    7 in total

    Run by

    Tagworks Pharmaceuticals BV

    See if you can join NCT06959706 on ClinicalTrials.gov

22. A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

    A FIH study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-kinase alpha (RAS-PI3Kα) inhibitor, as a single agent and in combination with either sotorasib or tr…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Virginia, Fairfax, Virginia

    Locations

    9 in total

    Run by

    Vividion Therapeutics, Inc.

    See if you can join NCT06804824 on ClinicalTrials.gov

23. PAS-004 in Patients With Advanced Solid Tumors

    The main purpose of this clinical trial is to test PAS-004 in people with advanced solid tumors with rat sarcoma virus (RAS), neurofibromatosis type I (NF1), or rapidly accelerated fibrosarcoma (RAF) mutations. The main questions it aims to answer are: * How well participants are able tolerate diff…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, Fairfax, Virginia

    Locations

    7 in total

    Run by

    Pasithea Therapeutics Corp.

    See if you can join NCT06299839 on ClinicalTrials.gov

24. A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

    This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site 102, Fairfax, Virginia

    Locations

    107 in total

    Run by

    DualityBio Inc.

    See if you can join NCT05914116 on ClinicalTrials.gov

25. A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

    This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutat…

    Stage

    Phase 1

    Ages

    18 to 89

    Site

    NEXT Virginia, Fairfax, Virginia

    Locations

    10 in total

    Run by

    Eikon Therapeutics

    See if you can join NCT06907043 on ClinicalTrials.gov